On 24 April 2007, the Annual General Meeting of H. Lundbeck A/S
resolved to reduce the company's share capital by a nominal amount of
DKK 29,338,220 by reducing the company's holding of treasury shares.
The resolution was announced in the electronic information system of
the Danish Commerce and Companies Agency on 2 May 2007, and the
statutory notice period has now expired with no claims received.
Accordingly, the reduction of the company's share capital was
registered with the Danish Commerce and Companies Agency today.
Following the reduction of capital, the nominal share capital of H.
Lundbeck A/S amounts to 1,034,353,145, equivalent to 206,870,629
The content of this release will have no influence on the Lundbeck
Group's financial result for 2007.
Jacob Tolstrup Caroline Broge
Investor Relations Manager, Media Relations Manager
North America +45 36 43 26 38
+1 201 350 0187
Stock Exchange Release No 282 - 3 August 2007
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit